EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis

Muhammad Anas Faheem, Bazil Azeem, Talha Ali, Rabia Asim, Tazheen Saleh Muhammad, Mata-E-Alla Dogar, Muhammad Abdullah Naveed

American Journal of Cardiovascular Drugs · 2026-07 · 26 (4) · 453-465

DOI: 10.1007/s40256-026-00798-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 02.05.2026. Verfasst von Muhammad Anas Faheem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Eicosapentaenoic Acid, Cardiovascular Diseases. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/OBJECTIVE: Residual cardiovascular risk persists despite intensive statin therapy in patients with established atherosclerotic cardiovascular disease (CVD). Omega-3 fatty acids, particularly high-dose eicosapentaenoic acid (EPA), have been proposed as adjunctive therapy, yet trial results conflict, likely due to formulation differences. We conducted a formulation-focused meta-analysis to determine whether high-dose EPA-dominant supplementation reduces cardiovascular events and to quantify the impact of mixed EPA/docosahexaenoic acid (DHA) regimens on efficacy. METHODS: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched MEDLINE, Embase, CENTRAL, and trial registries through May 2025 for randomized controlled trials, including placebo-controlled and open-label designs, of high-dose EPA-dominant omega-3 (≥ 1.8 g/day; ≥ 50% EPA) in adults with established CVD or other high-risk settings. Six trials (n = 42,738; 31-85% male) were eligible. Random-effects models generated pooled risk ratios (RRs), with I2 assessing heterogeneity; sensitivity analyses excluded mixed EPA/DHA formulations. Imaging surrogate outcomes were summarized narratively when study modalities were not directly comparable. RESULTS: EPA-based therapy significantly reduced hospitalizations for unstable angina (RR 0.75, 95% CI 0.66-0.87; I2 = 0%). Overall effects on recurrent myocardial infarction and revascularization were not statistically significant, but both became significant after exclusion of STRENGTH, the only mixed EPA/DHA cardiovascular outcomes trial. No significant effect was observed for ischemic stroke, cardiovascular death, or high-sensitivity C-reactive protein (hs-CRP). CHERRY and EVAPORATE both suggested attenuation of plaque progression, but these imaging studies were not pooled because intravascular ultrasound and coronary computed tomography angiography-derived measures were not directly comparable. CONCLUSION: High-dose EPA-dominant therapy was associated with fewer unstable angina hospitalizations, and formulation appeared to modify clinical benefit. Among blinded, placebo-controlled, cardiovascular outcomes trials, 4 g/day icosapent ethyl is the only formulation independently associated with reduced cardiovascular events. Larger formulation-specific trials are needed to clarify the roles of purified EPA, mixed EPA/DHA regimens, and patient selection. REGISTRATION: PROSPERO identifier number: CRD420251063069.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eicosapentaenoic AcidCardiovascular DiseasesHumansRandomized Controlled Trials as TopicDocosahexaenoic AcidsDietary Supplements

Substanzen

Eicosapentaenoic AcidDocosahexaenoic Acids

Autor:innen und Institutionen

  • Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan.
  • Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan. talhaali190@gmail.com.

Zitieren

APA

Faheem, M. A., Azeem, B., Ali, T., Asim, R., Muhammad, T. S., Dogar, M. E., & Naveed, M. A. (2026). Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 26(4), 453-465. https://doi.org/10.1007/s40256-026-00798-5

Vancouver

Faheem MA, Azeem B, Ali T, Asim R, Muhammad TS, Dogar ME, et al. Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs. 2026;26(4):453-465. doi:10.1007/s40256-026-00798-5

BibTeX
@article{Faheem2026,
  author = {Faheem, Muhammad Anas and Azeem, Bazil and Ali, Talha and Asim, Rabia and Muhammad, Tazheen Saleh and Dogar, Mata-E-Alla and Naveed, Muhammad Abdullah},
  title = {Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2026},
  volume = {26},
  number = {4},
  pages = {453--465},
  doi = {10.1007/s40256-026-00798-5}
}
Kostenlos starten →